266 related articles for article (PubMed ID: 23633494)
21. Immunosurveillance by antiangiogenesis: tumor growth arrest by T cell-derived thrombospondin-1.
Schadler KL; Crosby EJ; Zhou AY; Bhang DH; Braunstein L; Baek KH; Crawford D; Crawford A; Angelosanto J; Wherry EJ; Ryeom S
Cancer Res; 2014 Apr; 74(8):2171-81. PubMed ID: 24590059
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing.
Wang LX; Li R; Yang G; Lim M; O'Hara A; Chu Y; Fox BA; Restifo NP; Urba WJ; Hu HM
Cancer Res; 2005 Nov; 65(22):10569-77. PubMed ID: 16288050
[TBL] [Abstract][Full Text] [Related]
23. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
24. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control.
Vianello F; Papeta N; Chen T; Kraft P; White N; Hart WK; Kircher MF; Swart E; Rhee S; Palù G; Irimia D; Toner M; Weissleder R; Poznansky MC
J Immunol; 2006 Mar; 176(5):2902-14. PubMed ID: 16493048
[TBL] [Abstract][Full Text] [Related]
25. Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells.
Singh V; Ji Q; Feigenbaum L; Leighty RM; Hurwitz AA
J Immunother; 2009; 32(2):129-39. PubMed ID: 19238011
[TBL] [Abstract][Full Text] [Related]
26. Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation.
Kline J; Zhang L; Battaglia L; Cohen KS; Gajewski TF
J Immunol; 2012 Mar; 188(6):2630-42. PubMed ID: 22312128
[TBL] [Abstract][Full Text] [Related]
27. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo.
Liu C; Lewis CM; Lou Y; Xu C; Peng W; Yang Y; Gelbard AH; Lizée G; Zhou D; Overwijk WW; Hwu P
J Immunother; 2012 Apr; 35(3):276-82. PubMed ID: 22421945
[TBL] [Abstract][Full Text] [Related]
28. Host conditioning with IL-1β improves the antitumor function of adoptively transferred T cells.
Lee PH; Yamamoto TN; Gurusamy D; Sukumar M; Yu Z; Hu-Li J; Kawabe T; Gangaplara A; Kishton RJ; Henning AN; Vodnala SK; Germain RN; Paul WE; Restifo NP
J Exp Med; 2019 Nov; 216(11):2619-2634. PubMed ID: 31405895
[TBL] [Abstract][Full Text] [Related]
29. Optimization of T-cell Receptor-Modified T Cells for Cancer Therapy.
Drakes DJ; Rafiq S; Purdon TJ; Lopez AV; Chandran SS; Klebanoff CA; Brentjens RJ
Cancer Immunol Res; 2020 Jun; 8(6):743-755. PubMed ID: 32209638
[TBL] [Abstract][Full Text] [Related]
30. T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3.
Quatromoni JG; Morris LF; Donahue TR; Wang Y; McBride W; Chatila T; Economou JS
J Hematol Oncol; 2011 Nov; 4():48. PubMed ID: 22112546
[TBL] [Abstract][Full Text] [Related]
31. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection.
Schreurs MW; de Boer AJ; Figdor CG; Adema GJ
Cancer Res; 1998 Jun; 58(12):2509-14. PubMed ID: 9635569
[TBL] [Abstract][Full Text] [Related]
32. Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents.
Sharifzadeh Z; Rahbarizadeh F; Shokrgozar MA; Ahmadvand D; Mahboudi F; Jamnani FR; Moghimi SM
Cancer Lett; 2013 Jul; 334(2):237-44. PubMed ID: 22902507
[TBL] [Abstract][Full Text] [Related]
33. Pathogen-Boosted Adoptive Cell Transfer Therapy Induces Endogenous Antitumor Immunity through Antigen Spreading.
Xin G; Khatun A; Topchyan P; Zander R; Volberding PJ; Chen Y; Shen J; Fu C; Jiang A; See WA; Cui W
Cancer Immunol Res; 2020 Jan; 8(1):7-18. PubMed ID: 31719059
[TBL] [Abstract][Full Text] [Related]
34. Versatile strategy for controlling the specificity and activity of engineered T cells.
Ma JS; Kim JY; Kazane SA; Choi SH; Yun HY; Kim MS; Rodgers DT; Pugh HM; Singer O; Sun SB; Fonslow BR; Kochenderfer JN; Wright TM; Schultz PG; Young TS; Kim CH; Cao Y
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E450-8. PubMed ID: 26759368
[TBL] [Abstract][Full Text] [Related]
35. Intravital Imaging of Adoptive T-Cell Morphology, Mobility and Trafficking Following Immune Checkpoint Inhibition in a Mouse Melanoma Model.
Lau D; Garçon F; Chandra A; Lechermann LM; Aloj L; Chilvers ER; Corrie PG; Okkenhaug K; Gallagher FA
Front Immunol; 2020; 11():1514. PubMed ID: 32793206
[TBL] [Abstract][Full Text] [Related]
36. Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging.
Liu K; Liu X; Peng Z; Sun H; Zhang M; Zhang J; Liu S; Hao L; Lu G; Zheng K; Gong X; Wu D; Wang F; Shen L
Oncotarget; 2015 Sep; 6(27):23735-47. PubMed ID: 26124178
[TBL] [Abstract][Full Text] [Related]
37. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour.
Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F
Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440
[TBL] [Abstract][Full Text] [Related]
38. Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escape.
Kaluza KM; Kottke T; Diaz RM; Rommelfanger D; Thompson J; Vile R
Hum Gene Ther; 2012 Oct; 23(10):1054-64. PubMed ID: 22734672
[TBL] [Abstract][Full Text] [Related]
39. Immunosensitization with a Bcl-2 small molecule inhibitor.
Begley J; Vo DD; Morris LF; Bruhn KW; Prins RM; Mok S; Koya RC; Garban HJ; Comin-Anduix B; Craft N; Ribas A
Cancer Immunol Immunother; 2009 May; 58(5):699-708. PubMed ID: 18807035
[TBL] [Abstract][Full Text] [Related]
40. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression.
Chmielewski M; Kopecky C; Hombach AA; Abken H
Cancer Res; 2011 Sep; 71(17):5697-706. PubMed ID: 21742772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]